Clinical trials: Graft-vs-host Disease
Graft Versus Host Disease
Extracorporeal Photopheresis in Children and Young Adults With Refractory Acute Graft Versus Host Disease
Purpose : to evaluate the efficacy of ECP in children with refractory acute GVHD This study addresses patients with persistent GVHD after steroid and/or monoclonal antibody therapy
- Trial name
- NCT00824954
- Testing
- ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Clermont-Ferrand
Transplant-Related Disorder
Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model
To evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of child patients who are predicted to have a high risk for developing severe acute graftversus-host disease (aGVHD) by the dynamic aGVHD Onset…
- Trial name
- NCT05599256
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute-graft-versus-host Disease
Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease
This is a single arm phase 2 trial which includes patients with high risk acute GVHD defined as Ann Arbor score 2 or 3. The purpose of the study is to improve the outcome of these patients in terms of response to treatment and…
- Trial name
- NCT04291261
- Testing
- Uvadex
- Where
- 4 sites in Austria, Germany
- Volunteers
- 24 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Graft Versus Host Disease (cGvHD)
Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
Hematopoietic Stem Cell Transplant (HCT) has been used to treat children and adults who have leukemia, lymphoma and other cancers of blood and immune cells since the 1970s. For many of these forms of cancer, HCT works well.
- Trial name
- EVENT (NCT06991361)
- Testing
- EVE-Treg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sarah Nikiforow, MD
Sinusitis, Chronic, Cystic Fibrosis With Other Manifestations
SynRinse Irrigation Pilot (SIP) Trial
Assess if the use of SYNRINSE can improve short-term subjective and objective outcome measures after one week in patients with active Chronic Rhinosinusitis (CRS) who have had prior sinus surgery.
- Trial name
- NCT03154541
- Testing
- Synrinse
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Hematologic Malignancy
MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is evaluate the safety and tolerability of MPH966, a neutrophil elastase inhibitor, and its ability to prevent graft-versus-host disease after hematopoietic stem cell transplant.
- Trial name
- NCT03986086
- Testing
- MPH966
- Where
- United States
- Sponsor
- Nelson Chao
Graft Vs Host Disease
Post-transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Dose Reduction: 50 mg/kg vs 25 mg/kg
Allogeneic hematopoietic cell transplantation (HSCT) is a worldwide recognized therapy for several hematologic malignancies; a modality extensively used around the world due to its effectivity; however, an HLA-matched sibling or…
- Trial name
- NCT05780554
- Testing
- Cyclophosphamide
- Where
- Mexico
- Volunteers
- 42 people
- Sponsor
- Centro de Hematología y Medicina Interna
Graft Versus Host Disease
Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease
RATIONALE: Fludarabine may be an effective treatment for graft-versus-host disease caused by bone marrow transplantation. PURPOSE: Phase I/II trial to study the effectiveness of fludarabine in treating patients who have chronic…
- Trial name
- NCT00004194
- Testing
- fludarabine phosphate
- Sponsor
- Jonsson Comprehensive Cancer Center
Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD
This study is to assess the efficacy of Neihulizumab versus "conventional therapy" and to evaluate safety, pharmacokinetics and immunogenicity in treating steroid-refractory acute Graft-vs-Host Disease
- Trial name
- NCT02694770
- Testing
- Neihulizumab Treatment, Conventional Treatment
- Where
- 2 sites in United States
- Sponsor
- AbGenomics B.V Taiwan Branch
Graft Versus Host Disease, Acute Graft Versus Host Disease
BMT Autologous MSCs for GvHD
Subjects in this study have had an allogeneic (blood or marrow cells from another person) blood or marrow transplant to treat leukemia, lymphoma or other cancer of the blood, and have now developed Graft Versus Host Disease…
- Conditions
- Graft Versus Host Disease, Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease
- Trial name
- NCT02359929
- Testing
- Autologous mesenchymal stromal cells (MSCs)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Acute Graft Versus Host Disease
hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
This is a parallel controlled clinical study evaluating the safety and efficacy of hAECs in preventing aGVHD after HSCT.
- Trial name
- NCT06444022
- Testing
- Human amniotic epithelial stem cells（hAESCs）
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Myeloid Leukemia, in Relapse
Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
This is a retrospective and prospective non-interventional multicenter observational study. Neither diagnostic approaches nor experimental drugs/procedure will be applied and the samples will take place at the same time as the…
- Trial name
- GITMO-RELAPSE (NCT05124288)
- Testing
- Observations on Relapsed AML Allogeneic Transplanted patients
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Ciceri Fabio
Renal Anemia, Chronic
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis
This study will compare the efficacy and safety of subcutaneous Mircera and subcutaneous darbepoetin in the treatment of renal anemia in participants with chronic kidney disease who are not on dialysis and not receiving…
- Trial name
- NCT00559273
- Testing
- Methoxy polyethylene glycol-epoetin beta, Darbepoetin alfa
- Where
- 76 sites in Australia, Belgium and 14 more
- Volunteers
- 307 people
- Sponsor
- Hoffmann-La Roche
The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Ruxolitinib as GVHD Prophylaxis in AA Patients
Our study aimed to determine the prophylactic value of ruxolitinib for aGVHD in HSCT recipients of AA.Ruxolitinib was initiated at the beginning of conditioning regimen at 5 twice daily until 3 months post-transplantation.
- Trial name
- NCT05914714
- Testing
- Ruxolitinib 5 MG BID Oral Tablet
- Volunteers
- 46 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Graft vs Host Disease
Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
The purpose of this study is to determine whether low-doses alemtuzumab and rituximab combination are effective in the treatment of chronic graft-versus-host disease (GVHD) after first-line therapy failure.
- Trial name
- LowAR (NCT01042509)
- Testing
- Alemtuzumab and rituximab
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Steroid Refractory Acute Graft Versus Host Disease
Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease
This is a single-arm, open-label, multicenter study of the efficacy of UVADEX® (methoxsalen) Sterile Solution in conjunction with THERAKOS® CELLEX® Photopheresis Systems (ECP) in pediatric participants with steroid-refractory…
- Trial name
- NCT02524847
- Testing
- Methoxsalen, Extracorporeal Photopheresis (ECP)
- Where
- 32 sites in United States, Austria and 6 more
- Volunteers
- 29 people
- Sponsor
- Therakos, Inc., a Mallinckrodt Company
Graft Versus Host Disease, Acute
A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD.
- Trial name
- NCT05643638
- Testing
- CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs), Corticosteroids
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 65 people
- Sponsor
- Cynata Therapeutics Limited
cGVHD
Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)
Chronic graft-versus-host disease (cGvHD) is a serious condition that can happen after a stem cell or bone marrow transplant. The donor's immune cells attack the patient's body, causing inflammation, pain, and damage to organs…
- Trial name
- BELRUX (NCT07643025)
- Testing
- Belumosudil, Ruxolitinib
- Where
- Canada
- Volunteers
- 53 people
- Sponsor
- Dennis Kim
Bronchiolitis Obliterans Syndrome (BOS), HSCT
Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients
Allogeneic hematopoietic stem cell transplantation (HSCT) is burdened with a high morbidity and mortality rates. Graft versus host disease (GVHD) is the clinical manifestation of an immune conflict.
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS), HSCT, Bronchial Disease
- Trial name
- IMMUNO-BOS (NCT07771855)
- Testing
- Tezepelumab
- Where
- 6 sites in France
- Volunteers
- 36 people
- Sponsor
- Hopital Foch
Chronic Graft Versus Host Disease
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).
- Trial name
- NCT07127926
- Testing
- Belumosudil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center